Shots:

• Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East- Middle East and Africa (NEMEA) countries. Acino to get rights- title- and interest to the products in the portfolio exclusive in NEMEA. The transaction is expected to close in Q4’19
• Additionally- Takeda and Acino will sign multi-year manufacturing and supply agreement under which Takeda will continue to manufacture the products on behalf of Acino
• The collaboration will optimize Takeda’s portfolio in the NEMEA region- reduces its debt and accelerates deleveraging towards reaching its target of 2.0x net debt/adjusted EBITDA in the next 3-5yrs.

Click here to­ read full press release/ article 

Ref: Takeda| Image: Takeda